Kinex News
Back to headlines
October 30, 2008
Kinex completes another successful round of financing
Kinex Pharmaceuticals recently raised $3.4 million through a private placement among its existing shareholders. This round brings the total raised in equity capital and grants to approximately $15 million, since its inception in 2004.
Kinex is developing Next Generation Cancer Drugs and among them is KX2-391 that is currently in late Phase 1 human clinical trials. Several Phase 2 trials are in the planning stage and are scheduled to be launched in mid-2009. Kinex has used its proprietary technology platform to design and synthesize non-ATP competitive kinase inhibitors; a new class of drugs that promise to deliver effective therapy with minimal side effects. KX2-391 is being evaluated in patients with solid tumors in Phase 1 trials at MD Anderson Cancer Center, Roswell Park Cancer Institute and Fox Chase Cancer Institute.
The Company’s pipeline is focused on kinase targets for cancer and immunological-based diseases. A second cancer compound will enter full pre-clinical development later this year.